IMNM IMMUNOME INC revenue, earnings and financials
For the quarter ended June 30, 2026, IMMUNOME INC reported revenue of $0 (down 100.0% from a year earlier), net income of −$73.1M and diluted EPS of −$0.65; over the last four quarters revenue was $0 and net income −$254M; for the fiscal year ended December 2025 revenue was $6.94M, down 23.2% on the year before.
IMNM annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $6.94M, gross profit n/a, operating income −$224M, net income −$212M (margin -3060.0%), EPS −$2.43
- Fiscal year ended Dec 2024: revenue $9.04M, gross profit n/a, operating income −$306M, net income −$293M (margin -3240.4%), EPS −$5.00
- Fiscal year ended Dec 2023: revenue $14.0M, gross profit n/a, operating income −$110M, net income −$107M (margin -761.9%), EPS −$5.38
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$36.9M, net income −$36.9M (margin n/a), EPS −$3.09
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$25.2M, net income −$24.7M (margin n/a), EPS −$2.14
IMNM quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $0 (down 100.0% year over year), net income −$73.1M, EPS −$0.65
- Quarter ended Mar 31, 2026: revenue $0 (down 100.0% year over year), net income −$53.8M, EPS −$0.48
- Quarter ended Dec 31, 2025 (from the annual report): revenue $0 (down 100.0% year over year), net income −$69.9M, EPS −$0.76
- Quarter ended Sep 30, 2025: revenue $0 (down 100.0% year over year), net income −$57.5M, EPS −$0.65
- Quarter ended Jun 30, 2025: revenue $4.02M (up 69.8% year over year), net income −$43.4M, EPS −$0.50
- Quarter ended Mar 31, 2025: revenue $2.93M (up 184.4% year over year), net income −$41.6M, EPS −$0.52
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.74M (down 28.4% year over year), net income −$80.2M, EPS −$1.11
- Quarter ended Sep 30, 2024: revenue $2.91M (down 18.4% year over year), net income −$47.1M, EPS −$0.78
- Quarter ended Jun 30, 2024: revenue $2.36M (down 44.5% year over year), net income −$36.1M, EPS −$0.60
- Quarter ended Mar 31, 2024: revenue $1.03M (down 56.5% year over year), net income −$129M, EPS −$2.51
- Quarter ended Dec 31, 2023 (from the annual report): revenue $3.83M, net income −$92.6M, EPS −$4.21
- Quarter ended Sep 30, 2023: revenue $3.57M, net income −$4.35M, EPS −$0.36
- Quarter ended Jun 30, 2023: revenue $4.26M, net income −$5.56M, EPS −$0.46
- Quarter ended Mar 31, 2023: revenue $2.36M, net income −$4.27M, EPS −$0.35
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$7.79M, EPS −$0.64
- Quarter ended Sep 30, 2022: revenue n/a, net income −$8.53M, EPS −$0.75
- Quarter ended Jun 30, 2022: revenue n/a, net income −$8.92M, EPS −$0.74
- Quarter ended Mar 31, 2022: revenue n/a, net income −$11.7M, EPS −$0.96
- Quarter ended Dec 31, 2021 (from the annual report): revenue n/a, net income −$7.85M, EPS −$0.66
- Quarter ended Sep 30, 2021: revenue n/a, net income −$7.72M, EPS −$0.65
IMNM cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$191M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$111M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$7.57M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$28.7M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$18.2M, share buybacks n/a
IMNM balance sheet
- Jun 30, 2026: cash $218M, total assets $565M, total liabilities $40.3M, shareholders' equity $525M
- Mar 31, 2026: cash $583M, total assets $620M, total liabilities $31.1M, shareholders' equity $589M
- Dec 31, 2025: cash $653M, total assets $683M, total liabilities $48.8M, shareholders' equity $634M
- Sep 30, 2025: cash $273M, total assets $299M, total liabilities $35.5M, shareholders' equity $264M
- Jun 30, 2025: cash $144M, total assets $296M, total liabilities $27.0M, shareholders' equity $269M
- Mar 31, 2025: cash $258M, total assets $343M, total liabilities $35.6M, shareholders' equity $307M
- Dec 31, 2024: cash $143M, total assets $240M, total liabilities $59.1M, shareholders' equity $181M
- Sep 30, 2024: cash $156M, total assets $257M, total liabilities $42.0M, shareholders' equity $215M
What is IMNM's revenue?
IMMUNOME INC reported $0 of revenue over its last four quarters, through June 30, 2026.
Is IMNM profitable?
No. IMMUNOME INC lost $254M over the last four quarters.
What is IMNM's EPS?
Diluted earnings per share over the last four quarters were −$2.54; −$0.65 in the latest quarter.